U.S. markets closed

  • S&P 500

    3,936.97
    -65.90 (-1.65%)
     

  • Dow 30

    32,030.11
    -530.49 (-1.63%)
     

  • Nasdaq

    11,669.96
    -190.15 (-1.60%)
     

  • Russell 2000

    1,727.36
    -50.38 (-2.83%)
     

  • Crude Oil

    70.03
    +0.36 (+0.52%)
     

  • Gold

    1,971.90
    +30.80 (+1.59%)
     

  • Silver

    23.04
    +0.62 (+2.74%)
     

  • EUR/USD

    1.0859
    +0.0087 (+0.80%)
     

  • 10-Yr Bond

    3.5000
    -0.1060 (-2.94%)
     

  • GBP/USD

    1.2266
    +0.0046 (+0.38%)
     

  • USD/JPY

    131.2650
    -1.1950 (-0.90%)
     

  • Bitcoin USD

    27,118.67
    -997.46 (-3.55%)
     

  • CMC Crypto 200

    590.71
    -25.23 (-4.10%)
     

  • FTSE 100

    7,566.84
    +30.62 (+0.41%)
     

  • Nikkei 225

    27,466.61
    +520.94 (+1.93%)
     

Global Antiviral Therapy Market to Surpass USD 79.8 Million and Rise at a CAGR of 6.7% Owing to COVID-19 Chaos by 2026 – Exclusive Report [150 Pages] by Research Dive

Research Dive
·4 min read

The COVID-19 outbreak has positively impacted the global antiviral therapy market in 2020. The growing prevalence of infectious diseases across the globe is predicted to propel the global market growth during the forecast period.

New York, USA, Dec. 14, 2020 (GLOBE NEWSWIRE) -- According to a Research Dive published report, the global antiviral therapy market valued for $48.1 million in 2018 and is estimated to garner $79.8 million by 2026, rising at a CAGR of 6.7% from 2019 to 2026.

Impact on Market Due to Outbreak of COVID-19

The global antiviral therapy industry is predicted to witness an upsurge in growth rate during the forecast period, due to the COVID-19 outbreak. As per the report, the antiviral therapy market was likely to rise at a CAGR of 5.8% from 2019 to 2026 prior to COVID-19 crisis. However, due to the COVID-19 pandemic, the global market is projected to rise at a CAGR of 6.7% over the forecast period. This is mainly owing to the growing prevalence of hepatitis C and human immunodeficiency virus (HIV) across the globe. Comprehensive analysis on drivers, challenges, opportunities, restraints, and strategies executed by various governments and market players across the globe are further provided in the report.

---------------------------------------------------------------------------------------------------------------------------------------------------------
As we are running Anniversary Discount, here are some additional benefits which you are entitled to avail with this report.

  • Free Excel Data Pack

  • The report will cover impact of COVID-19 on this market.

  • 20% Free Customisation

  • 16 analyst hours support

  • Quarterly Update on Enterprise License

  • 24 hours priority response

  • Additional Two company profile as per our requirement

*Offer Valid till 31 December 2020

Connect with Our Analyst to Reveal Anniversary Offers in detail: https://www.researchdive.com/connect-to-analyst/246

---------------------------------------------------------------------------------------------------------------------------------------------------------

Current Market Scenario Due to COVID-19

The COVID-19 pandemic has impacted the global antiviral therapy market in a positive way in 2020. The anticipated pre COVID-19 market size for antiviral therapy market was $53.6 million in 2020 and is expected to observe a strong growth and reach up to $54.7 million due to COVID-19 pandemic. The progressive growth of the market is majorly attributed to growing focus of key players to develop drugs for the treatment of COVID-19. For instance, in May 2020, Cipla and Gilead Sciences entered into a collaboration for the production & distribution of the investigational medicine that is being used for the treatment of COVID-19 affected patients.

Global Market to Continue to Grow Enormously Post-Pandemic

The global antiviral therapy market is anticipated to continue to observe a massive growth post-coronavirus pandemic. This is mainly due to the rapidly growing emergence rate of infectious diseases in various parts of the world. In addition, changing environmental & global setup and surging geriatric population around the world are other factors expected to fuel the global market growth after the COVID-19 pandemic.

Recent Developments by Key Market Players

The key players operating in the global antiviral therapy industry are adopting several strategies to hold a robust position in the global industry. For instance, in April 2020, a leading biopharmaceutical venture, Ennaid Therapeutics, LLC announced to be advancing the development of ENU200, for the treatment of COVID-19 infected patients. ENU200 is an orally deliverable, patent-pending, and repurposed antiviral drug that is previously approved by the U.S. FDA for a different indication.

For More Detail Insights, Download Sample Copy of the Report at: https://www.researchdive.com/download-sample/246

The leading global antiviral therapy market players include -

  1. F. Hoffmann-La Roche Ltd

  2. GlaxoSmithKline plc.

  3. Bristol-Myers Squibb Company

  4. Merck & Co., Inc.

  5. Informa plc.

  6. Cipla Inc.

  7. Dr. Reddy’s Laboratories Ltd.

  8. AbbVie Inc.

  9. Gilead Sciences, Inc.

  10. Johnson & Johnson Services, Inc.

The report summarizes and provides various aspects of all the key players functioning in the overall market such as financial performance, product portfolio, recent developments, strategic moves, SWOT analysis, and many more. Quick Download Top Companies Development Strategies Summary Report

Trending Reports -


CONTACT: Mr. Abhishek Paliwal Research Dive 30 Wall St. 8th Floor, New York NY 10005 (P) +91-(788)-802-9103 (India) +1-(917)-444-1262 (US) Toll Free: 1-888-961-4454 E-mail: support@researchdive.com Website: https://www.researchdive.com Blog: https://www.researchdive.com/blog/ LinkedIn: https://www.linkedin.com/company/research-dive/ Twitter: https://twitter.com/ResearchDive Facebook: https://www.facebook.com/Research-Dive-1385542314927521


Recommended Stories

  • 'Invite me to your funeral': Jim Cramer makes a bold call on the Nasdaq — and even billionaire Elon Musk had to respond. Here are 3 ways to bet on that conviction

    Mad Money or a mad call?

  • Leaked Documents Show Amazon Made an Enormous Mistake

    The last year has seen a large number of job layoffs in the technology sector. Major companies like Salesforce, ESPN, Microsoft, Google, and Meta Platforms have all announced cuts to staffing -- a move that has been largely attributed to the rapid growth of online tech during the covid-19 lockdown. Amazon is one of the biggest companies announcing waves of job cuts -- in January, the company let go of more than 2,300 employees in the payments, health care, human resources, robotics, and web services departments.

  • Wall Street Bulls Look Optimistic About Medical Properties (MPW): Should You Buy?

    Based on the average brokerage recommendation (ABR), Medical Properties (MPW) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

  • Ford F-150 Lightning recall reveals cause of battery fire

    The National Highway Traffic Safety Administration has revealed the root cause of the battery fires that halted Ford F-150 Lightning production.

  • Ask an Advisor: I'm a 43-Year-Old Divorced Dad With $315K in an IRA, $90K in a Roth and Other Accounts. Can I Retire at 57?

    I am a 43-year-old divorced father. I have $315,000 in a traditional individual retirement account (IRA), $90,000 in a Roth IRA, $22,000 in a health savings account (HSA), $8,000 in a 529 college savings account, $30,000 in a traditional 401k, … Continue reading → The post Ask an Advisor: I'm a 43-Year-Old Divorced Dad With $315K in an IRA, $90K in a Roth and Other Accounts. Can I Retire at 57? appeared first on SmartAsset Blog.

  • US STOCKS-Wall St ends sharply lower after Powell warns inflation fight continues

    Wall Street gyrated to end sharply lower on Wednesday after the U.S. Federal Reserve delivered a widely expected 25 basis point policy hike, while hinting that it was on the verge of pausing future increases in view of recent turmoil in the financial sector. The three major U.S. stock indexes, which were mostly directionless prior to the Fed announcement, jumped higher then deflated as investors digested the accompanying statement and Chair Jerome Powell's subsequent Q&A session. "The market was encouraged when it heard that the Fed had considered pausing completely and then it was disappointed when Powell clarified that their hands weren’t tied and that they can keep raising rates if they need to," said Chris Zaccarelli, chief investment officer at Independent Advisor Alliance in Charlotte, North Carolina.

  • George Soros and Steve Cohen Have One Thing in Common: They Both Bet on These 2 Stocks

    In this uncertain market environment, the educated investor would do well to seek out some signal that can cut through the noise and indicate the sound stock purchase choices. Following the legendary investors, the traders who build multi-billion dollar fortunes on the stock market trading scene, is a popular strategy – and when two of those investing legends agree… well, there’s a stock that should definitely get a second look. George Soros and Steve Cohen have both built fortunes, for themselv

  • Elon Musk says what he thinks the Fed should do with interest rates

    Elon Musk on late Monday offered his opinion on what the Federal Reserve should do with its benchmark interest rate. The Fed's FOMC is meeting for two days this week.

  • 'Big Short' Michael Burry Sounds the Alarm on Two U.S. Banks

    The legendary investor indicates that more than 60% of Comerica and U.S. Bancorp deposits are uninsured.

  • Stock market news today: Stocks smoked after Federal Reserve raises rates by 0.25%

    U.S. stocks moved higher Wednesday after the Federal Reserve raised interest rates by quarter percentage point amid a fast-moving banking crisis.

  • ‘Load Up,’ Says Raymond James About These 3 ‘Strong Buy’ Stocks

    The last few weeks have been rocky, with the collapse of Silicon Valley Bank, and the crypto-heavy Silvergate and Signature banks, dominating the headlines. For a short time, it seemed that the contagion would spread to the global financial giants. Now, however, it appears that we’ve managed to avoid a true banking crisis – and Raymond James’ chief investment officer Larry Adam has pointed out several reasons why. For starters, Adam notes that Credit Suisse, despite its troubles, found a way out

  • CDC Rings Alarm About Deadly Fungus. 6 Things to Know.

    The number of infections from the Candida Auris fungus, which can be deadly for people who are already sick, is small but rapidly growing.

  • How Do I Avoid Paying Tax on Dividends?

    Dividends are payments that some companies make to shareholders to reward them for investing in them. Dividends can provide regular, predictable income to investors who also preserve the chance of profiting from price appreciation. Dividends can qualify for advantageous capital … Continue reading → The post How Do I Avoid Paying Tax on Dividends? appeared first on SmartAsset Blog.

  • GE Is Splitting in Two. Here’s What the Parts Are Worth.

    Wolfe Research analyst Nigel Coe took a look at what GE Aerospace and GE Vernova will be worth on a stand-alone basis. GE Vernova, GE's power generation businesses, are due to be spun out in early 2024.

  • Delta Move Is Bad News For Southwest, United Airlines Passengers

    Airfare prices move up and down based on two major things -- passenger demand and the cost of actually flying the plane. Domestic air travel traffic for 2022 rose 10.9% compared to the prior year. The nation's air traffic in 2022 was at 79.6% of the full-year 2019 level.

  • The Fed Has Overseen a Remarkable Transfer of Wealth From Bondholders to Taxpayers

    The same dynamics that have left some banks reeling have handed taxpayers a windfall. The Fed will have to navigate them, David Beckworth writes.

  • First Republic shares drop 11% as Yellen says Treasury won't insure all deposits

    NEW YORK (Reuters) -As beleaguered First Republic Bank considers its options, Treasury Secretary Janet Yellen said on Wednesday there is no discussion on insurance for all deposits, making a "bull case" scenario more difficult for the stock. First Republic, whose shares have lost much of their value since the banking crisis started in the U.S. on March 8, is among the banks speaking to peers and investment firms about potential deals in the wake of U.S. regulators taking over Silicon Valley Bank and Signature Bank this month following bank runs. Morgan Stanley analyst Manan Gosalia, in a report earlier this week, set a target price of $54 for First Republic shares.

  • U.S. Bancorp Dispels Doom Scenarios

    The regional bank says it's not facing a bank run as investors fear risk of contagion after Silicon Valley Bank collapse.

  • UBS set for talks with Michael Klein to terminate Credit Suisse investment bank deal - FT

    UBS on Sunday agreed to buy rival Swiss bank Credit Suisse for 3 billion Swiss francs ($3.23 billion) in stock and agreed to assume up to 5 billion francs ($5.4 billion) in losses, in a shotgun merger engineered by Swiss authorities to avoid more market-shaking turmoil in global banking. Klein, a veteran dealmaker, was merging his eponymous advisory boutique into Credit Suisse's investment banking operations to create CS First Boston as a standalone business which he would have led from New York. UBS has now assigned a legal team to examine how to void the contract Credit Suisse signed with Klein in the cheapest way possible, according to the FT report, which cited people with direct knowledge of the matter.

  • Is Trending Stock Bank of America Corporation (BAC) a Buy Now?

    Zacks.com users have recently been watching Bank of America (BAC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.